We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 1,151

Federal Circuit Finds "Consisting Of" Requires Reversing Infringement Of Shire Lialda Patent
  • Foley & Lardner LLP
  • USA
  • February 14 2017

The Federal Circuit focused on the “consisting of” language in the claims at issue when it reversed the district court’s finding that Watson’s ANDA


Court Rejects Theory Of Derivation Based On FDA Requirement
  • Foley & Lardner LLP
  • USA
  • February 7 2017

The Federal Circuit decision in Cumberland Pharmaceuticals Inc. v. Mylan Institutional LLC may be more interesting for what Mylan argued than for


CAFC Upholds Preliminary Injunction Despite Unpatentability Ruling of PTAB
  • Foley & Lardner LLP
  • USA
  • February 1 2017

This week in Tinnus Enterprises LLC v. Telebrands Corp. (Moore, Wallach and Stoll), the Federal Circuit upheld the grant of a preliminary injunction


Federal Circuit Finds Infringement Under Akamai Of Two-Step Method Of Treatment
  • Foley & Lardner LLP
  • USA
  • January 24 2017

In Eli Lilly & Co. v. Teva Parenteral Medicines, Inc., the Federal Circuit affirmed the district court decision finding infringement under Akamai of


Federal Circuit Finds Infringement Under Akami Of Two-Step Method Of Treatment
  • Foley & Lardner LLP
  • USA
  • January 24 2017

In Eli Lilly & Co. v. Teva Parenteral Medicines, Inc., the Federal Circuit affirmed the district court decision finding infringement under Akami of a


How Will Trump Change The FDA?
  • Foley & Lardner LLP
  • USA
  • January 20 2017

President-elect Trump's plans for his first 100 days in office include "cutting the red tape at the FDA" and "speeding the approval of life-saving


Supreme Court Will Judge Biosimilar Patent Dance
  • Foley & Lardner LLP
  • USA
  • January 16 2017

The U.S. Supreme Court has agreed to review some of the patent dispute resolution provisions of the Biologics Price Competition and Innovation Act


Federal Circuit Questions Standing For IPR Appeals
  • Foley & Lardner LLP
  • USA
  • January 11 2017

As I have written previously, neither the statutes nor the regulations governing Inter Partes Review (IPR) require the party challenging the patent


Federal Circuit Finds IPR Petitioner Lacks Standing To Appeal
  • Foley & Lardner LLP
  • USA
  • January 10 2017

Yesterday in Phigenix, Inc. v. Immunogen, Inc., the Federal Circuit held that petitioner Phigenix lacked standing to appeal an adverse final written


International Trade Litigation and the New Trump Administration: Your Top Ten Questions Answered
  • Foley & Lardner LLP
  • USA
  • January 6 2017

Globalization and the need to efficiently deploy corporate resources have led many multinational companies to establish global supply